Profile data is unavailable for this security.
About the company
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-38.25m
- Incorporated2018
- Employees42.00
- LocationVincerx Pharma Inc260 Sheridan Avenue, Suite 400PALO ALTO 94306United StatesUSA
- Phone+1 (650) 800-6676
- Fax+1 (302) 655-5049
- Websitehttps://vincerx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Raphael Pharmaceutical Inc | 0.00 | -1.57m | 18.66m | 0.00 | -- | -- | -- | -- | -0.0929 | -0.0929 | 0.00 | -0.0055 | 0.00 | -- | -- | -- | -624.25 | -- | -- | -- | -- | -- | -- | -- | -- | -173.44 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
KALA BIO Inc | 0.00 | -39.55m | 18.67m | 43.00 | -- | 2.80 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
Synlogic Inc | 3.21m | -73.22m | 18.84m | 6.00 | -- | 1.41 | -- | 5.88 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
Biomx Inc | 0.00 | -26.17m | 18.86m | 58.00 | -- | 5.10 | -- | -- | -0.5433 | -0.5433 | 0.00 | 0.067 | 0.00 | -- | -- | 0.00 | -74.18 | -- | -101.74 | -- | -- | -- | -- | -- | -- | -21.95 | 0.7841 | -- | -- | -- | 7.59 | -- | -- | -- |
Cocrystal Pharma Inc | 0.00 | -16.75m | 19.33m | 12.00 | -- | 0.8559 | -- | -- | -1.65 | -1.65 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -52.03 | -50.94 | -56.92 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
Evaxion Biotech A/S - ADR | 73.00k | -22.13m | 19.40m | 49.00 | -- | -- | -- | 265.75 | -81.29 | -81.29 | 0.2665 | -1.25 | 0.0042 | -- | 0.091 | 1,489.80 | -126.74 | -100.11 | -183.85 | -131.65 | -- | -- | -30,308.22 | -131,560.30 | -- | -30.92 | 1.77 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
Nymox Pharmaceutical Corp | 0.00 | -4.87m | 19.58m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
Indaptus Therapeutics Inc | 0.00 | -14.98m | 19.64m | 7.00 | -- | 2.10 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
Sol Gel Technologies Ltd | 1.55m | -27.24m | 19.64m | 36.00 | -- | 0.5082 | -- | 12.64 | -1.02 | -1.02 | 0.0574 | 1.39 | 0.0338 | -- | 0.3774 | 43,166.67 | -59.27 | -31.60 | -64.80 | -35.49 | -- | -- | -1,752.77 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
Goldenwell Biotech Inc | 2.34k | -116.90k | 19.80m | -- | -- | 233.71 | -- | 8,461.54 | -0.0012 | -0.0012 | 0.00002 | 0.0009 | 0.0098 | 0.0071 | -- | -- | -49.07 | -- | -52.16 | -- | 47.01 | -- | -4,995.73 | -- | 37.75 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
Vincerx Pharma Inc | 0.00 | -38.25m | 20.15m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
MEI Pharma Inc | 66.75m | 26.16m | 20.72m | 46.00 | 0.7923 | 0.4061 | 0.7816 | 0.3104 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
Polypid Ltd | 0.00 | -24.25m | 21.25m | 59.00 | -- | 2.97 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
Lumos Pharma Inc | 1.53m | -37.13m | 21.27m | 33.00 | -- | 1.22 | -- | 13.94 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
AIM ImmunoTech Inc | 193.00k | -31.12m | 21.28m | 26.00 | -- | 5.04 | -- | 110.24 | -0.637 | -0.637 | 0.004 | 0.096 | 0.0072 | -- | 0.2189 | 7,423.08 | -116.00 | -45.64 | -148.40 | -48.35 | 74.09 | -231.75 | -16,123.32 | -11,695.01 | -- | -- | 0.3478 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
Holder | Shares | % Held |
---|---|---|
Prosight Management LPas of 25 Apr 2024 | 2.50m | 9.11% |
Sage Rhino Capital LLCas of 31 Mar 2024 | 1.70m | 6.22% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 1.00m | 3.65% |
Point72 Asset Management LPas of 31 Mar 2024 | 954.83k | 3.48% |
Rock Springs Capital Management LPas of 31 Mar 2024 | 891.72k | 3.25% |
BofA Securities, Inc.as of 31 Mar 2024 | 701.42k | 2.56% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 661.04k | 2.41% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 631.49k | 2.30% |
Kingdon Capital Management LLCas of 31 Mar 2024 | 385.00k | 1.41% |
ExodusPoint Capital Management LPas of 31 Mar 2024 | 316.64k | 1.16% |